Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.

Cyclooxygenase-2 in Synaptic Signaling

Open access
Yang, Hongwei, Chen, Chu · 2008 · Current Pharmaceutical Design

Abstract

Cyclooxygenase-2 (COX-2), a rate-limiting enzyme converting arachidonic acid to prostaglandins and a key player in neuroinflammation, has been implicated in the pathogenesis of neurodegenerative diseases such as multiple sclerosis, Parkinson's and Alzheimer's diseases, and in traumatic brain injury- and ischemia-induced neuronal damage, and epileptogenesis. Accumulated information suggests that the contribution of COX-2 to neuropathology is associated with its involvement in synaptic modification. Inhibition or elevation of COX-2 has been shown to suppress or enhance excitatory glutamatergic neurotransmission and long-term potentiation (LTP). These events are mainly mediated via PGE(2), the predominant reaction product of COX-2, and the PGE(2) subtype 2 receptor (EP(2))-protein kinase A pathway. Recent evidence shows that endogenous cannabinoids are substrates for COX-2 and can be oxygenated by COX-2 to form new classes of prostaglandins (prostaglandin glycerol esters and prostaglandin ethanolamides). These COX-2 oxidative metabolites of endocannabinoids, as novel signaling mediators, modulate synaptic transmission and plasticity and cause neurodegeneration. The actions of these COX-2 metabolites are likely mediated by mitogen-activated protein kinase (MAPK) and inositol 1,4,5-trisphosphate (IP(3)) signal transduction pathways. These discoveries suggest that the contributions of COX-2 to neurotransmission and brain malfunction result not only from its conversion of arachidonic acid to classic prostaglandins but also from its oxidative metabolism of endocannabinoids to novel prostaglandins. Thus, elucidation of COX-2 in synaptic signaling may provide a mechanistic basis for designing new drugs aimed at preventing, treating or alleviating neuroinflammation-associated neurological disorders.

Overview

Integrity signals

Registry

Crossref · 10.2174/138161208784480144

Cites

139 of 139 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 138 references

Cited by

See all 197

Metadata

Authors
Yang, H., & Chen, C.
Affiliations
Louisiana State University Health Sciences Center New Orleans (US)
Venue
Current Pharmaceutical Design
Published
2008-05-01
Volume
14
Issue
14
Pages
1443-1451
ISSN
1381-6128 (ISSN-L)
OpenAlex
W2083843309
Cited by
195
References
138
Citations by year
2026: 7 · 2025: 10 · 2024: 10 · 2023: 7 · 2022: 10 · 2021: 15 · 2020: 13 · 2019: 5 · 2018: 14 · 2017: 7 · 2016: 9 · 2015: 5 · 2014: 10 · 2013: 10 · 2012: 9
FWCI
12.61
Type
journal article
Language
en
Open access
Locations
  • Current Pharmaceutical Design (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke (R01NS054886)
  • National Center for Research Resources (P20RR-16816, P20RR016816)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
Keywords
cyclooxygenase-2, synaptic signaling, prostaglandin E2, endocannabinoids, neuroinflammation, long-term potentiation, glutamatergic neurotransmission, synaptic plasticity, neurodegenerative diseases, traumatic brain injury, ischemic neuronal injury, epileptogenesis, MAPK signaling, IP3 signaling, COX-2 inhibitors
MeSH terms
Animals, Humans, Synaptic Transmission, Neuronal Plasticity, Oxidation-Reduction, Synapses, Drug Design, Dinoprostone, Signal Transduction, Receptors, Prostaglandin E, Cyclooxygenase 2, Receptors, Prostaglandin E, EP2 Subtype, Cannabinoid Receptor Modulators

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cyclooxygenase-2 in Synaptic Signaling. https://app.cochat.ai/papers/10.2174/138161208784480144
The paper
Yang, H., & Chen, C. (2008). Cyclooxygenase-2 in Synaptic Signaling. Current Pharmaceutical Design. https://doi.org/10.2174/138161208784480144

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.